Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
ALLO - Allogene Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.43
DETAILS
HIGH:
$9.00
LOW:
$3.85
MEDIAN:
$6.42
CONSENSUS:
$6.43
UPSIDE:
207.66%
Stock News
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
Allogene Therapeutics, Inc. $ALLO Shares Bought by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP grew its stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 25.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,201,655 shares of the company's stock after acquiring an additional 243,839 shares during the quarter. Dimensional Fund Advisors
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
Allogene Therapeutics Q2 Earnings Call Highlights
Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO-316, and plans to report initial data from the ALLO-329 autoimmune program by year-end.
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2026.
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report second quarter 2026 financial results and provide a business update on August 12, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $8.52 Consensus Price Target from Analysts
Shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel's Potential to Transform Disease Treatment in First-Line LBCL Consolidation Cema-Cel Induced Rapid and Substantial MRD Clearance of 58.3%, with a 97.7% Median Decrease in Plasma ctDNA at Day 45, Compared With a 26.6% Median Increase in the Observation Arm Cema-Cel Was Well-Tolerated, With Most Patients Managed in the Outpatient Setting and No Hospitalizations for Treatment-Related Adverse Events FDA Also Granted Fast Track Designation to Cema-Cel for the ALPHA3 Development Program RMAT and Fast Track Status Enable Enhanced FDA Engagement and Support Potential Expedited Development and Review Pathways SOUTH SAN FRANCISCO, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to cemacabtagene ansegedleucel (cema-cel) for the treatment of adult patients with large B-cell lymphoma (LBCL) who, at the completion of first-line (1L) therapy, are in complete or partial response suitable for observation but test positive for minimal residual disease (MRD).
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All Responders Progression-Free at the Time of Analysis Responses Range from 8 to 18+ Months, with Median Overall Survival Not Yet Reached Safety Profile was Manageable with Proactive Diagnostic and Management Strategies Effective in Mitigating IEC-HS ALLO-316 Demonstrated Robust Expansion and Tumor Infiltration Following Standard Lymphodepletion, Validating the Dagger ® Technology as a Next-Generation Allogeneic CAR T Platform SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of complete Phase 1 data from the TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma (RCC) in the Journal of Clinical Oncology.
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering.
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics Announces Planned CEO Succession
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Dr. David Chang, M.D., Ph.D., will transition from his role as President and Chief Executive Officer, effective June 30, 2026, following eight years of leadership that established Allogene as a leader in the development of off-the-shelf cell therapies. Dr. Chang will continue to serve on the Company's Board of Directors.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences.
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics Q1 Earnings Call Highlights
Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April financing.
Allogene Therapeutics ends China cell therapy deal with Overland
Allogene Therapeutics said on Wednesday it has ended a key partnership for developing cell therapies in parts of Asia and reworked its equity stake in partner Overland Therapeutics.
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended March 31, 2026.
Price Targets
Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein
$3.85
(was $3.06)
Bernstein
Allogene Therapeutics price target raised to $9 from $7 at Baird
$9.00
(was $3.06)
Robert W. Baird
Allogene (ALLO) PT Lowered to $9 at H.C. Wainwright
$9.00
(was $2.98)
Debjit Chattopadhyay
·
H.C. Wainwright
Allogene (ALLO) PT Lowered to $7 at B.Riley
$7.00
(was $2.90)
Kalpit Patel
·
B.Riley Financial
Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird
$11.00
(was $9.74)
Jack Allen
·
Robert W. Baird
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
$35.00
(was $15.29)
Michael Schmidt
·
Guggenheim
Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord
$55.00
(was $17.62)
John Newman
·
Canaccord Genuity
Allogene (ALLO) PT Lowered to $30 at Jefferies
$30.00
(was $13.13)
Biren Amin
·
Jefferies
Allogene Therapeutics price target lowered to $35 from $60 at Roth Capital
$35.00
(was $13.13)
Anthony Butler
·
Roth Capital
Allogene (ALLO) PT Lowered to $32 at BofA Securities
$32.00
(was $13.13)
Jason Gerberry
·
Bank of America Securities
Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer
$40.00
(was $13.13)
Mark Breidenbach
·
Oppenheimer
Allogene Therapeutics upgraded to Outperform from Market Perform at Raymond James
$36.00
(was $27.64)
Dane Leone
·
Raymond James